The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

November 21, 2006 07:01 ET

Medipattern Appoints Vice President, Sales & Marketing to Launch New Sales Strategy

TORONTO, ONTARIO--(CCNMatthews - Nov. 21, 2006) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided diagnosis (CAD) software applications for medical imaging, is very pleased to announce the appointment of Janet Sterritt to the position of Vice President, Sales and Marketing. This appointment is the first in Medipattern's newly focused sales strategy and reflects the Company's increasing industry profile and growing direct relationships with original equipment manufacturers (OEMs).

Janet Sterritt is a proven senior executive with a strong background in the CAD market, specifically relating to women's health. During the past 13 years, Ms Sterritt has served in several key roles with iCAD. Most recently, she was Vice President of Women's Heath and as such was key in developing business relationships with all of the new digital mammography developers, including GE Medical Systems, Siemens, Hologic, FujiFILM, Agfa, Kodak, PlanMed, Sectra, and IMS Giotto. Among her many accomplishments, Ms Sterritt diversified iCAD's strategy to target CAD development; led the team delivering CAD products; and played a key role in several acquisitions that led to the creation and expansion of iCAD. She has rolled out consistently successful product strategies for imaging products, taken new CAD products through the insurance and regulatory approval processes, and worked with sales staff to build significant recognition and market share. Ms Sterritt has a unique, hands-on knowledge of all aspects of the CAD marketplace, and also contributes substantially on the public education side as a volunteer.

"Janet's energy and commitment are evident from her past successes," said Jeff Collins, President and CEO of Medipattern. "Attracting someone of her stature is an indication of how much Medipattern has accomplished in a very short time, and her inclusion in the Medipattern team will add significant industry knowledge and experience as well as a strong base of contacts among our target customer base. We see Janet's appointment as the anchor position in a growing sales team for Medipattern as its product line expands."

"CAD in screening mammography has proven its efficacy by detecting more cancers at earlier stages, making it a medical necessity - a fact recognized by insurance companies as well as the medical profession," said Janet Sterritt. "The next logical step is to use CAD more widely in breast ultrasound and breast MR to improve workflow, accuracy in diagnosis, and secure record keeping. Medipattern is well positioned as the market technology innovator and leader in these areas. Breast cancer can strike any woman regardless of heritage, diet, or physical fitness. Reaching the correct diagnosis earlier is key to beating this disease - and this is exactly where B-CAD™ helps. I am honoured to join the team and look forward to making CAD a recognized medical necessity for all the imaging modalities."

Ms Sterritt's appointment coincides with the withdrawal of Kerr Spencer from the role of Vice President, Sales and Marketing, for personal and health reasons. "We thank Kerr for his contribution, and wish him well in the future," said Jeff Collins.

Upcoming Events:

Medipattern will be at the Radiology Society of North America conference, November 26 to November 30, 2006, and plans to demonstrate its software at the Kodak, Confirma, and Cedara booths.

Medipattern's annual general meeting is to be held December 7, 2006 at 10:00 AM EST in the boardroom of WeirFoulds in the Exchange Tower, Suite 1600, 130 King Street West in Toronto. Please contact Robin Sundstrom at 416-368-8770 x223 if you plan to attend.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and the award-winning B-CAD MRI™. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Please visit the company's website at: www.medipattern.com.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information